Literature DB >> 26780402

Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity.

Michela Pecoraro1, Mariagiovanna Del Pizzo1, Stefania Marzocco1, Rosalinda Sorrentino1, Michele Ciccarelli2, Guido Iaccarino2, Aldo Pinto1, Ada Popolo3.   

Abstract

Doxorubicin (DOXO) is commonly used to treat a wide range of malignant tumors, but its clinical use is limited by acute and chronic cardiotoxicity. The precise mechanism underlying DOXO-induced cardiotoxicity is still not completely elucidated, but cardiac inflammation seems to be involved. Effects of DOXO on proinflammatory cytokines, inflammatory cell infiltration, and necrosis have been proven only when a functional impairment has already occurred, so this study aimed to investigate the acute effect of DOXO administration in mouse heart. The results of our study demonstrated alterations in cardiac function parameters assessed by ultrasound within 24h after a single injection of DOXO, with a cumulative effect along the increase of the dose and the number of DOXO administrations. At the same time, DOXO causes a significant production of proinflammatory cytokines (such as TNF-α and IL-6) with a concomitant reduction of IL-10, a well-known antiinflammatory cytokine. Furthermore, overexpression of inducible nitric oxide synthase (iNOS) in heart tissue and increased levels of serum nitrite in DOXO-treated mice were detected. Notably, DOXO administration significantly increased nitrotyrosine expression in mouse heart. Our data support the hypothesis that these early events, could be responsible for the later onset of more severe deleterious remodeling leading to DOXO induced cardiomyopathy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiotoxicity; Cytokines; Doxorubicin; Inflammation; Nitric oxide

Mesh:

Substances:

Year:  2016        PMID: 26780402     DOI: 10.1016/j.taap.2016.01.006

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  39 in total

1.  All-trans-retinoic acid ameliorates doxorubicin-induced cardiotoxicity: in vivo potential involvement of oxidative stress, inflammation, and apoptosis via caspase-3 and p53 down-expression.

Authors:  Asmaa F Khafaga; Yasser S El-Sayed
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-10-30       Impact factor: 3.000

2.  Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats.

Authors:  Mohammad Sheibani; Sadaf Nezamoleslami; Hedyeh Faghir-Ghanesefat; Amir Hossein Emami; Ahmad Reza Dehpour
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-08       Impact factor: 3.333

Review 3.  In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.

Authors:  Serena L'Abbate; Michela Chianca; Iacopo Fabiani; Annamaria Del Franco; Alberto Giannoni; Giuseppe Vergaro; Chrysanthos Grigoratos; Claudia Kusmic; Claudio Passino; Yuri D'Alessandra; Silvia Burchielli; Michele Emdin; Daniela Maria Cardinale
Journal:  J Cardiovasc Transl Res       Date:  2022-03-21       Impact factor: 4.132

4.  Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway.

Authors:  Ferhat Dindaş; Hüseyin Güngör; Mehmet Ekici; Pınar Akokay; Füsun Erhan; Mustafa Doğduş; Mehmet Birhan Yılmaz
Journal:  Anatol J Cardiol       Date:  2021-11       Impact factor: 1.596

Review 5.  Prevention of Anthracycline-Induced Cardiotoxicity: The Good and Bad of Current and Alternative Therapies.

Authors:  Nonhlakanipho F Sangweni; Derick van Vuuren; Lawrence Mabasa; Kwazi Gabuza; Barbara Huisamen; Sharnay Naidoo; Reenen Barry; Rabia Johnson
Journal:  Front Cardiovasc Med       Date:  2022-06-22

Review 6.  Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.

Authors:  Anchit Bhagat; Eugenie S Kleinerman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction.

Authors:  Himangshu Sonowal; Pabitra Pal; Kirtikar Shukla; Ashish Saxena; Satish K Srivastava; Kota V Ramana
Journal:  Biochem Pharmacol       Date:  2018-02-16       Impact factor: 5.858

8.  Fisetin, a plant flavonoid ameliorates doxorubicin-induced cardiotoxicity in experimental rats: the decisive role of caspase-3, COX-II, cTn-I, iNOs and TNF-α.

Authors:  Tao Ma; Amit D Kandhare; Anwesha A Mukherjee-Kandhare; Subhash L Bodhankar
Journal:  Mol Biol Rep       Date:  2018-10-25       Impact factor: 2.316

Review 9.  Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches.

Authors:  Mohammad Sheibani; Yaser Azizi; Maryam Shayan; Sadaf Nezamoleslami; Faezeh Eslami; Mohammad Hadi Farjoo; Ahmad Reza Dehpour
Journal:  Cardiovasc Toxicol       Date:  2022-01-21       Impact factor: 3.231

Review 10.  Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.

Authors:  Simona Serini; Renata Ottes Vasconcelos; Renata Nascimento Gomes; Gabriella Calviello
Journal:  Int J Mol Sci       Date:  2017-12-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.